About TRACON Pharmaceuticals (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc. for the development and commercialization of TRC105; and Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122 for the ophthalmology indications of TRC105, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio-2.24
Forward P/E Ratio-2.76
Sales & Book Value
Annual Sales$8.76 million
Price / Sales5.09
Price / CashN/A
Book Value$0.97 per share
Price / Book2.59
EPS (Most Recent Fiscal Year)($1.14)
Return on Equity-96.65%
Return on Assets-52.95%
TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions
What is TRACON Pharmaceuticals' stock symbol?
TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."
How were TRACON Pharmaceuticals' earnings last quarter?
TRACON Pharmaceuticals (NASDAQ:TCON) announced its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09. TRACON Pharmaceuticals had a negative return on equity of 96.65% and a negative net margin of 201.21%. View TRACON Pharmaceuticals' Earnings History.
When is TRACON Pharmaceuticals' next earnings date?
What price target have analysts set for TCON?
1 analysts have issued 1-year target prices for TRACON Pharmaceuticals' stock. Their predictions range from $6.00 to $6.00. On average, they expect TRACON Pharmaceuticals' share price to reach $6.00 in the next year. View Analyst Ratings for TRACON Pharmaceuticals.
Who are some of TRACON Pharmaceuticals' key competitors?
Some companies that are related to TRACON Pharmaceuticals include Pluristem Therapeutics (PSTI), Organovo (ONVO), Aptose Biosciences (APTO), Krystal Biotech (KRYS), Eiger Biopharmaceuticals (EIGR), Aevi Genomic Medicine (GNMX), Applied Genetic Technologies (AGTC), Curis (CRIS), Cidara Therapeutics (CDTX), Genocea Biosciences (GNCA), aTyr Pharma (LIFE), Brainstorm Cell Therapeutics (BCLI), CytRx (CYTR), Champions Oncology (CSBR) and BiondVax (BVXV).
Who are TRACON Pharmaceuticals' key executives?
TRACON Pharmaceuticals' management team includes the folowing people:
- Dr. Charles P. Theuer, CEO, Pres & Director (Age 54)
- Ms. Patricia L. Bitar CPA, Chief Financial Officer, Treasurer and Assistant Sec. (Age 59)
- Mr. H. Casey Logan, Chief Bus. Officer (Age 46)
- Dr. Sharon Real Ph.D., Sr. VP of Product Devel. (Age 54)
- Ms. Bonne Adams M.B.A., Sr. VP of Clinical Operations (Age 41)
When did TRACON Pharmaceuticals IPO?
(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.
Has TRACON Pharmaceuticals been receiving favorable news coverage?
News coverage about TCON stock has trended somewhat negative on Thursday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TRACON Pharmaceuticals earned a news sentiment score of -0.10 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.60 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are TRACON Pharmaceuticals' major shareholders?
TRACON Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include PUISSANCE CROSS-BORDER OPPORTUNITIES V LLC (15.50%). Company insiders that own TRACON Pharmaceuticals stock include Enterprise Associates 14 New, Peter W Sonsini, Ronald L Shazer and William R Larue. View Institutional Ownership Trends for TRACON Pharmaceuticals.
How do I buy shares of TRACON Pharmaceuticals?
Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TRACON Pharmaceuticals' stock price today?
One share of TCON stock can currently be purchased for approximately $2.51.
How big of a company is TRACON Pharmaceuticals?
TRACON Pharmaceuticals has a market capitalization of $48.81 million and generates $8.76 million in revenue each year. The biopharmaceutical company earns $-19,100,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. TRACON Pharmaceuticals employs 25 workers across the globe.
How can I contact TRACON Pharmaceuticals?
TRACON Pharmaceuticals' mailing address is 4350 La Jolla Village Drive Suite 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]
MarketBeat Community Rating for TRACON Pharmaceuticals (TCON)MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.
TRACON Pharmaceuticals (NASDAQ:TCON) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
TRACON Pharmaceuticals (NASDAQ TCON) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 37.88%
TRACON Pharmaceuticals (NASDAQ TCON) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/27/2018||Enterprise Associates 14 New||Major Shareholder||Buy||707,964||$2.70||$1,911,502.80|| |
|6/2/2017||William R Larue||Director||Sell||2,500||$2.69||$6,725.00||13,388|| |
|11/29/2016||Peter W Sonsini||Major Shareholder||Buy||869,565||$5.75||$4,999,998.75|| |
|6/3/2016||Ronald L Shazer||Insider||Sell||1,003||$7.48||$7,502.44||335|| |
|10/16/2015||Jafco Super V3 Investment Limi||Major Shareholder||Sell||1,500||$9.90||$14,850.00||1,497,053|| |
|10/15/2015||Jafco Super V3 Investment Limi||Major Shareholder||Sell||5,300||$10.16||$53,848.00||1,498,553|| |
|10/13/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||3,168||$10.01||$31,711.68||1,503,853|| |
|10/9/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||1,448||$10.01||$14,494.48||1,503,853|| |
|10/8/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||21,920||$10.10||$221,392.00||1,507,021|| |
|10/5/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||15,100||$10.08||$152,208.00||1,528,941|| |
|9/25/2015||Jafco Super V3 Investment Limi||Major Shareholder||Sell||7,600||$12.13||$92,188.00||1,544,041|| |
|9/24/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||22,303||$12.99||$289,715.97||1,551,641|| |
|9/22/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||39,426||$14.02||$552,752.52||1,573,944|| |
|9/21/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||18,200||$14.48||$263,536.00||1,573,944|| |
|9/18/2015||Charles Theuer||CEO||Sell||10,000||$17.34||$173,400.00|| |
|9/18/2015||H Casey Logan||insider||Sell||5,000||$17.34||$86,700.00|| |
|9/17/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||42,344||$11.78||$498,812.32||1,613,370|| |
|9/14/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||60,038||$11.78||$707,247.64||1,655,714|| |
|9/10/2015||Charles Theuer||CEO||Sell||3,516||$12.00||$42,192.00|| |
|9/9/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||12,000||$10.71||$128,520.00||1,715,752|| |
|9/8/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||5,700||$10.47||$59,679.00||1,715,752|| |
|9/4/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||6,600||$10.48||$69,168.00||1,715,752|| |
|9/3/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||15,300||$10.51||$160,803.00||1,740,052|| |
|9/1/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||14,000||$10.42||$145,880.00||1,755,352|| |
|8/24/2015||Jafco Super V3 Investment Limi||Major Shareholder||Sell||3,000||$11.00||$33,000.00||1,769,352|| |
|8/20/2015||Jafco Super V3 Investment Limi||major shareholder||Sell||10,683||$11.36||$121,358.88||1,772,352|| |
|8/18/2015||Jafco Super V3 Investment Limi||Major Shareholder||Sell||11,174||$11.71||$130,847.54|| |
|8/13/2015||Jafco Super V3 Investment Limi||Major Shareholder||Sell||9,361||$11.60||$108,587.60|| |
|2/4/2015||M James Barrett||Major Shareholder||Buy||500,000||$10.00||$5,000,000.00|| |
TRACON Pharmaceuticals (NASDAQ TCON) News Headlines
|TRACON Pharmaceuticals (TCON) Rating Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - April 18 at 3:33 PM
|TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted ...|
globenewswire.com - April 10 at 5:29 PM
|TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors|
finance.yahoo.com - April 9 at 8:19 AM
|Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors|
www.prnewswire.com - April 4 at 4:12 PM
|Edited Transcript of TCON earnings conference call or presentation 28-Feb-18 9:30pm GMT|
finance.yahoo.com - April 1 at 8:22 AM
|TRACON Pharmaceuticals Inc (TCON) Major Shareholder Enterprise Associates 14 New Buys 707,964 Shares|
www.americanbankingnews.com - March 27 at 10:14 PM
|TRACON Pharmaceutical (TCON) Announces $38.7 Million Private Placement of Common Stock and Warrants|
www.streetinsider.com - March 26 at 8:24 AM
|TRACON Pharma secures $38.7M capital raise; shares off 5%|
seekingalpha.com - March 24 at 5:14 PM
|TRACON Pharmaceuticals Announces $38.7 Million Private Placement - GlobeNewswire (press release)|
globenewswire.com - March 24 at 8:50 AM
|TRACON Pharmaceuticals Announces $38.7 Million Private Placement|
finance.yahoo.com - March 23 at 5:41 PM
|TRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference|
finance.yahoo.com - March 21 at 5:37 PM
|TRACON Pharmaceuticals to Present at 30th Annual ROTH ... - GlobeNewswire (press release)|
globenewswire.com - March 7 at 8:19 AM
|TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference - GlobeNewswire (press release)|
www.globenewswire.com - March 7 at 8:19 AM
|TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference|
finance.yahoo.com - March 6 at 5:40 PM
|TRACON Pharmaceuticals Inc (TCON) to Post FY2018 Earnings of $0.75 Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - March 5 at 4:46 AM
|TRACON Pharmaceuticals (TCON) Posts Earnings Results, Beats Expectations By $0.09 EPS|
www.americanbankingnews.com - March 1 at 11:18 AM
|Tracon Pharmaceuticals' (TCON) CEO Charles Theuer on Q4 2017 ... - Seeking Alpha|
seekingalpha.com - March 1 at 8:16 AM
|TRACON Pharmaceuticals Q4 Earnings Preview|
finance.yahoo.com - February 28 at 6:03 PM
|TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update|
finance.yahoo.com - February 28 at 6:03 PM
|Analysts Expect Breakeven On The Horizon For TRACON Pharmaceuticals Inc (NASDAQ:TCON)|
finance.yahoo.com - February 28 at 8:18 AM
|Did TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) Recent Earnings Growth Beat The Trend?|
finance.yahoo.com - February 26 at 8:18 AM
|$710,000.00 in Sales Expected for TRACON Pharmaceuticals Inc (TCON) This Quarter|
www.americanbankingnews.com - February 23 at 2:32 PM
|TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018|
finance.yahoo.com - February 21 at 5:26 PM
| Brokerages Expect TRACON Pharmaceuticals Inc (TCON) to Announce -$0.45 EPS|
www.americanbankingnews.com - February 21 at 3:16 AM
|TRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on Monday|
www.americanbankingnews.com - February 19 at 4:44 AM
| Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $710,000.00|
www.americanbankingnews.com - February 6 at 10:12 AM
|TRACON Pharmaceuticals Inc (TCON) Expected to Announce Earnings of -$0.45 Per Share|
www.americanbankingnews.com - February 4 at 3:18 AM
|TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients|
finance.yahoo.com - January 19 at 3:44 PM
|TRACON Pharmaceuticals Reports Granting of Inducement Awards|
finance.yahoo.com - January 18 at 6:17 PM
| Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share|
www.americanbankingnews.com - January 18 at 5:08 AM
|Financial Analysis: TRACON Pharmaceuticals (TCON) & Its Peers|
www.americanbankingnews.com - January 11 at 8:18 AM
|TRACON Pharmaceuticals (TCON) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - January 5 at 12:32 PM
|Critical Survey: TRACON Pharmaceuticals (TCON) vs. Its Rivals|
www.americanbankingnews.com - January 3 at 10:14 AM
|ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 27, 2017|
finance.yahoo.com - December 27 at 1:07 PM
|TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017|
finance.yahoo.com - December 26 at 12:44 PM
|Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China|
www.bizjournals.com - December 21 at 3:39 PM
|TRACON Pharmaceuticals and Ambrx Announce Development and ... - GlobeNewswire (press release)|
www.globenewswire.com - December 21 at 11:32 AM
|35 Stocks Moving In Thursday's Pre-Market Session - Benzinga|
www.benzinga.com - December 21 at 11:32 AM
|TRACON Pharmaceuticals (TCON) and Ambrx Enter Pact for ... - StreetInsider.com|
www.streetinsider.com - December 21 at 11:32 AM
|TRACON Pharmaceuticals and Ambrx Announce Development and Commercialization Agreement for TRC105 in China|
finance.yahoo.com - December 21 at 11:32 AM
|Contrasting TRACON Pharmaceuticals (TCON) and Its Rivals|
www.americanbankingnews.com - December 18 at 3:28 AM
|$710,000.00 in Sales Expected for TRACON Pharmaceuticals, Inc. (TCON) This Quarter|
www.americanbankingnews.com - December 17 at 4:30 AM
|TRACON Pharmaceuticals Announces Appointment of Brian Daniels, MD, to Scientific Advisory Board - GlobeNewswire (press release)|
globenewswire.com - December 5 at 12:04 PM
|TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board|
finance.yahoo.com - December 5 at 12:04 PM
|TRACON Doses First Patient in Phase 1b Study of TRC105 with Opdivo® in Patients with Lung Cancer|
finance.yahoo.com - November 30 at 11:49 AM
|Zacks: Analysts Anticipate TRACON Pharmaceuticals, Inc. (TCON) Will Post Quarterly Sales of $710,000.00|
www.americanbankingnews.com - November 29 at 8:44 AM
|TRACON Pharmaceuticals, Inc. (TCON) Expected to Post Quarterly Sales of $710,000.00|
www.americanbankingnews.com - November 29 at 6:50 AM
|TRACON Pharmaceuticals, Inc. (TCON) Expected to Announce Earnings of -$0.45 Per Share|
www.americanbankingnews.com - November 27 at 9:14 AM
|TRACON Pharmaceuticals, Inc. (TCON) Expected to Post Earnings of -$0.45 Per Share|
www.americanbankingnews.com - November 27 at 9:14 AM
|34 Stocks Moving In Tuesday's Pre-Market Session - Benzinga|
www.benzinga.com - November 14 at 3:47 PM
TRACON Pharmaceuticals (NASDAQ:TCON) SEC Filings
This page is loading this company's SEC Filings. Please wait...
TRACON Pharmaceuticals (NASDAQ:TCON) Income Statement, Balance Sheet and Cash Flow Statement
TRACON Pharmaceuticals (NASDAQ TCON) Stock Chart for Thursday, April, 26, 2018